Clinical trials: Antiplatelet Drug
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Post Polypectomy Bleeding
Safety of Cold Snare Polypectomy in Patients With Uninterrupted Antiplatelet Agent
Polypectomy is regarded as high risk for bleeding. Several guidelines recommend continuous use of aspirin during polypectomy. However for clopidogrel, widely used antiplatelet agent, cessation of 5-7 is recommended.
- Trial name
- NCT04328987
- Testing
- cold snare polypectomy
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Incheon St.Mary's Hospital
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Ischemic Stroke, Antiplatelet Effect
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults.
- Trial name
- NCT04142151
- Testing
- Sanchitongshu, Aspirin, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Renal Failure, Coronary Artery Disease
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes)…
- Conditions
- Renal Failure, Coronary Artery Disease, Hemolysis
- Trial name
- NCT03330223
- Testing
- Clopidogrel group;Ticagrelor group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Drug Resistance
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of age, whereas biological resistance, associated with an increased risk of cardiovascular events, is observed in about 20-30% of younger…
- Trial name
- CEPAGE (NCT04990596)
- Testing
- additional blood sample
- Where
- 4 sites in France
- Volunteers
- 37 people
- Sponsor
- Rennes University Hospital
Atherothrombosis
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.
- Trial name
- ASTERIAS (NCT02616497)
- Testing
- Aspirin, Triflusal
- Where
- Greece
- Volunteers
- 1,220 people
- Sponsor
- University of Ioannina
Minor Stroke
Thrombolysis of Urokinase for Minor Stroke
This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of…
- Trial name
- TRUST (NCT04420351)
- Testing
- Urokinase thrombolysis, Aspirin;Clopidogrel
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Bleeding, Platelet Dysfunction Due to Drugs
Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets
This study aims to determine whether cold-stored platelets (CSP) are equally, more effective, or uniquely effective at reversing the effect of dual antiplatelet therapy in healthy human subjects compared to…
- Conditions
- Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
- Trial name
- R-DAPT (NCT03787927)
- Testing
- Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bloodworks
Gastrointestinal Injury, Ischemic Heart Disease
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in patients with coronary artery disease. However, antiplatelet therapy may have adverse consequences, the most common of which is gastrointestinal…
- Trial name
- OPT-PEACE (NCT03198741)
- Testing
- Aspirin + clopidogrel, Clopidogrel monotherapy, Aspirin monotherapy
- Where
- China
- Volunteers
- 783 people
- Sponsor
- Shenyang Northern Hospital
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Angina Pectoris
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
Use of high loading doses of clopidogrel (antiplatelet drug) just before coronary interventions is associated with improved outcomes after coronary stenting.
- Trial name
- SASSICAIA (NCT02548611)
- Testing
- Prasugrel, Clopidogrel
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 795 people
- Sponsor
- LMU Klinikum
Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR)
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy…
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07374718
- Testing
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shenyang Northern Hospital
ST Elevation Myocardial Infarction
STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT
Primary percutaneous coronary intervention (PCI) is the preferred revascularization strategy for patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- STARS DAPT (NCT05785897)
- Testing
- Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
- Where
- 2 sites in Switzerland
- Volunteers
- 350 people
- Sponsor
- IGLESIAS Juan Fernando
Diabetes
Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The aim of the first project is to…
- Trial name
- PANDDA (NCT02302508)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg